Skip to content

Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle

Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03174470
Enrollment
20
Registered
2017-06-02
Start date
2016-11-02
Completion date
2017-06-30
Last updated
2019-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Ejaculation

Brief summary

The company suggests a new concept of treatment for PE: Transient inhibition of striated muscle contraction by a transcutaneous stimulation device. This study aim is to evaluate the safety of delivering increasing electrical stimulation intensities to the subject's perineum, using a TENS technique and equipment, followed by a 72-hour postoperative follow-up.

Interventions

DEVICETENS Stimulator

Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle

Sponsors

Virility Medical Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Generally healthy * Ability to follow study instructions and complete study assessment tools

Exclusion criteria

* History of cardiovascular disorders * Any type of implanted pacemaker/defibrillator * Hypertension * Diabetes Mellitus * Local dermatological disease * Local skin irritation/lesions * Any neurological disorder * Any psychiatric disease and/or psychiatric medications

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Treatment-Emergent Adverse EventsBaselinePain sensation score given by all subjects, as well as their verbal description of what they sensed during the various stimulations

Secondary

MeasureTime frameDescription
Incidence of post-treatment Adverse Events72 hoursPost treatment safety evaluation completed by subjects (using safety questionnaire)

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026